Escaping the burden of

bacterial re-infections

Our core mission is to contribute to global health by providing innovative active immunotherapy to help patients and healthcare systems overcome the clinical burden of bacterial re-infections caused by drug-resistant pathogens.

ANTIMICROBIAL RESISTANCE (AMR)

One of the world's most pressing medical problems

1.27M

Die each year from AMR, and the number is increasing by the day

10M

Deaths from AMR each year by 2050, which is a bigger killer than cancer

€100 Trillion

Financial burden from AMR, reducing global economic output by up to 3.5%

Antibiotics are standard of care for bacterial infections, but their overuse and misuse is the root-cause for AMR!

WHAT WE DO

About our technology

Proxi Biotech is an innovative biotech company with a focus on utilizing its proprietary and patent-pending technology platform for the development of novel, safe and highly immunogenic toxoid-based active immunotherapy.

PIPELINE

TARGETING HIGH-PRIORITY UNMET NEEDS

recurrent Clostridium difficile infection

recurrent urinary tract infection

About our programs

FOLLOW OUR PROJECTS

rj@proxibiotech.com